Printer Friendly

PATENT OFFICE ALLOWS EXOCELL PATENT

PATENT OFFICE ALLOWS EXOCELL PATENT
 PHILADELPHIA, Sept. 8 /PRNewswire/ -- Exocell, Inc., today announced that the U.S. Patent Office has allowed its patent covering unique cell lines that produce monoclonal antibodies targeted to glycohemoglobin. Exocell scientists are developing products based on this technology for diabetes management applications.
 Glycohemoglobin is formed when sugar reacts with hemoglobin, the oxygen carrying protein in red blood cells. The amount of glycohemoglobin formed in the body depends on the concentration of sugar in the blood. Diabetics have high levels of glycohemoglobin when diabetes is not well controlled. Exocell's E85 monoclonal antibodies, covered by this patent, are the first that are uniquely targeted to the sugar part of glycohemoglobin. Their development allows for improved diabetes management with new tests of greater specificity and simplicity to monitor diabetic control.
 "Monoclonal antibodies of glycohemoglobin represents a breakthrough," said Dr. Rex Clements, vice president of medical affairs, Novo-Nordisk Pharmaceuticals Inc. "This unique technology will allow assessment of the efficacy of diabetes treatment rapidly and specifically."
 Exocell has gained FDA clearance for marketing several products, based on its proprietary technology, dedicated to diabetes management. Exocell's E85 monoclonal antibodies are part of a family of unique biologic agents that the company has developed for diagnostic and therapeutic applications in diabetes. Exocell is in discussion with pharmaceutical manufacturers for licensing its E85 and other monoclonal antibody technologies.
 /delval/
 -0- 9/8/92
 /CONTACT: M.P. Cohen, M.D., scientific director (press), 215-222-5515, or C.J. Newman, M.D. (companies of investors), 212-446-3306, both for Exocell/ CO: Exocell, Inc. ST: Pennsylvania IN: MTC SU:


TW -- DC020 -- 6954 09/08/92 11:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 8, 1992
Words:270
Previous Article:FPL HURRICANE ANDREW RESTORATION OVERVIEW
Next Article:STEWART FOODS, INC. ANNOUNCES RESIGNATION OF DOUGLAS J. STANARD AS PRESIDENT AND CHIEF OPERATING OFFICER
Topics:


Related Articles
EUROPEAN PATENT OFFICE ALLOWS TECHNICLONE PATENT APPLICATION
NEW TREATMENT DISCOVERED TO PREVENT DIABETIC EYE DISEASE
Broad Claims Allowed on Pioneer Corn Transformation Patent Application by U.S. Patent Office
Exocell and Boehringer Mannheim Reach Settlement
USPTO grants patent related to human reproductive cloning.
Arena Pharmaceuticals receives United States patent.
Zyomyx strengthens biochip patent estate.
Government.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters